RRM1 and familial pancreatic carcinoma: A recent meta-analysis revealed that patients with high RRM1 expression had largely poorer OS and DFS than those with low RRM1 expression [46,47], suggesting that the expression of RRM1 is an indicator of poor survival in patients with pancreatic cancer accepting gemcitabine chemotherapy [46].